The evolution of knowledge about the inflammatory bowel diseases
Authors:
MUDr. Petr Hrabák; MUDr. Pavel Hrabák; MUDr. Markéta Štajnerova; MUDr. Aleš Novotný; MUDr. CSc. Karel Lukáš
Authors‘ workplace:
IV. interní klinika 1. LF UK a VFN, U Nemocnice 2, Praha 2, 128
08
Published in:
Čas. Lék. čes. 2016; 155: 84-87
Category:
Review Articles
Overview
Crohn’s disease and ulcerative colitis has affected people for many centuries however its incidence most likely used to be very low. The knowledge of the idiopathic intestinal inflammation at that time was also very limited – an interest about the disease has emerged since the second half of 19th century. Despite all the progress in medicine its etiology still remains unclear.
Diagnosis had for a long been based only on clinical investigation and later radiography, endoscopy came in to use in the 1970s. First significant advances in therapy came during the 1940s and 1950s with the invention of aminosalicylates, antibiotics and corticoids. The most advanced conservative therapy today is biological treatment although the importance of gastrointestinal surgery should not be overlooked.
The aim of this article is to briefly review the development of knowledge of the idiopathic intestinal inflammation with an emphasis on the 20th century.
Keywords:
inflammatory bowel diseases, ulcerative colitis, Crohn’s disease
Sources
1. Morgagni GB. The seats and causes of disease investigated by anatomy. In: Johnson and Payne (eds.). Five Books Containing a Great Variety of Dissections with Remarks (Translated from the Latin of John Baptist Morgagni by Benjamin Alexander). In Three Volumes. A Millar and T Cadell, London, 1769.
2. Wilsk S. Morbid appereances in the intestine of Miss Bankes. London Medical Gazzette 1859; 2: 264.
3. Kirschner JB. The historical antecedents of inflammatory bowel disease concepts. In: Inflammatory Bowel disease (4th ed.). Williams and Wilkins, Baltimore, 1994; 3–27.
4. Lockhart-Mummery JP. The causes of colitis: with special reference to its surgical treatment, with an account of 36 cases. Lancet 1907; 1: 1638.
5. Lee S, Crean M. History of Radiology. European Society of Radiology, 2012. URL: www.myESR.org
6. Dalziel TK. Chronic interstitial enteritis. Br Med J (Clin Res) 1913; 2: 1068–1070.
7. Gill AM. Chronic ulcerative colitis clinical experiments with pig’s intestine. Lancet 1944; 246: 536–537.
8. Cheney G. Injection of highly concentrated liver extract in treatment of idiopathic ulcerative colitis. Arch Intern Med 1939; 63: 813–829.
9. Logan AH. Chronic ulcerative colitis cured with iodine. Med Clin North Am 1923; 7: 105–112.
10. Phillips S. A discussion on ulcerative colitis. Proc R Soc Med 1909; 2: 88–90.
11. Hurst AF. Ulcerative colitis. Guys Hosp Rep 1921; 71: 26–41.
12. Leusden JT. Observation of colitis ulceration with a contribution to the knowledge of the patogenetic effects of colon bacilli. Ned Tijdschr Geneeskd 1921; 2: 2890–2905.
13. Lups S, Baker AJ. Vaccine therapy in ulcerative colitis. Am J Dig Dis 1935; 2: 139–160.
14. Bargen J, Logan A. The etiology of chronic ulcerative colitis: experimental studies with suggestions for a more rational form of treatment. Arch Intern Med 1925; 36: 818–829.
15. Strauss AA. Ulcerative colitis. Surg Clin North Am 1923; 3: 1033–1042.
16. Crohn BB, Ginzburg L, Openheimer GD. Regional ileitis: a pathological and clinical entity. JAMA 1932; 99: 1323–1329.
17. Brown PW, Bargen JA, Weber HM. Chronic inflammatory lesion of the small intestine, regional enteritis. Am J Dig Dis 1934; 1: 426–431.
18. Murray CD. Psychogenic factors in the etiology of ulcerative colitis. Am J Dig Dis 1930; 180: 239–247.
19. Almy TP, Tulin M. Alterations in colonic function in man under stress. I. Experimental production of changes simulating the irritable colon. Gastroenterology 1947; 8: 616–626.
20. Andresen AFR. Ulcerative colitis – an allergic phenomenon. Am J Dig Dis 1942; 9: 91–96.
21. Domagk G. Ein Beitrag zur Chemotherapie der Bakteriellen Infektionen. Deutsch Med Wochenschr 1935; 61: 250–253.
22. Svartz N. Salazopyrin – a new sulfanilamide preparation. A. Therapeutic result in rheumatoid arthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations on treatment with sulfanilamide preparations. Acta Med Scand 1942; 110: 577–590.
23. Pelnář J. Pathologie a therapie nemocí vnitřních II. Bursík a Kohout, Praha, 1934, s. 190, 231.
24. Mařatka Z. Colitis ulcerosa. Česká grafická unie, Praha, 1948.
25. Dixon CF. Regional enteritis. Ann Surg 1938; 108: 857–866.
26. Cave HW, Thompson JE. Mortality factors in the surgical treatment of ulcerative colitis. Ann Surg 1941; 114: 46–55.
27. Job EE, Finkelstein A. Interesting X-ray findings in a case of acute fulminating ulcerative colitis. Gastroenterology 1947; 8: 213–220.
28. Morson BC, Lockhart-Mummery HE. Crohn’s disease of the colon, Gastroenterologia 1959; 92: 168–173.
29. Janowitz HD, Lindner AE, Marshak RH. Granulomatous colitis. JAMA 1965; 191: 121–124.
30. Crockett RW. Psychiatric findings in Crohn’s disease. Lancet 1952; 1: 946–949.
31. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11 dehydrocorticosterone) (compound E) and of pituitary adenocorticotropic hormone on rheumatoid arthritis preliminary report. Proc Staff Meet Mayo Clin 1949; 24: 181–197.
32. Truelove SC, Witts IJ. Cortisone in ulcerative colitis. Report on therapeutic trial. Br Med J 1955; 2: 1041–1048.
33. Levy R, Wilkins H, Herrmann J et al. Experiences with prefrontal lobotomy for intractable ulcerative colitis; preliminary report. JAMA 1956; 160: 1277–1280.
34. Brooke BN. The management of an ileostomy, including its complications. Lancet 1952; 2: 102–104.
35. Kirsner JB, Spencer JA. Family occurrences of ulcerative colitis, regional enteritis, and ileocolitis. Ann Int Med 1963; 59: 133–144.
36. Kirsner JB, Goldgraber MB. Hypersensitivity, autoimmunity and the digestive tract. Gastroenterology 1960; 38: 536–562.
37. Gould SR. Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet 1975; 2: 988.
38. Provenzale L, Camerata R, Revignas A. Lacoloscopia totale trans-anale mediante una metodica originale (osservazioni preliminari). Rass Med Sarda 1966; 69: 149–160.
39. Mařatka Z. Paměti. Karolinum, Praha, 1977.
40. Nedbal J, Mařatka Z. Colitis ulcerosa v Československu. Vnitř Lék 1967; 13: 1054–1063.
41. Mařatka Z, Nedbal J. Dnešní stav diagnostiky a terapie zánětlivých nemocí tlustého střeva. In: Mařatka Z (ed.). Pokroky v gastroenterologii. Avicenum, Praha, 1975; 283–300.
42. Mařatka Z, Nedbal J, Niederle B et al. Operations for severe ulcerative colitis with reference to advantages of ileorectal anastomosis over permanent ileostomy. Proc R Soc Med 1966; 59: 129–130.
43. Vokurka V. Imunologické pojetí ulcerosní kolitidy. Thomayerova sbírka 436. SZN, Praha, 1965.
44. Bitter J, Dyrhonová V, Komárková O a kol. Nespecifické střevní záněty v České republice. Čs Gastroenterol Výž 1992; 46: 313–321.
45. Bean RHD. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49: 592–593.
46. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 1975; 20: 721–724.
47. Azad-Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–895.
48. Kozarek RA, Patterson DJ, Gelfand MD et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–356.
49. Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol 2004; 42: 1129–1135.
50. Robertson DJ, Sandler RS. Measles virus and Crohn’s disease: a critical appraisal of the current literature. Inflamm Bowel Dis 2001; 7: 51–57.
51. Lawson RD, Coyle WJ. The noncolonic microbiome: does it really matter? Curr Gastroenterol Rep 2010; 12: 259–262.
52. Li M, Wang B, Zhang M et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117–2122.
53. Morgan XC,Tickle TL, Sokol H et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.
54. Guthy E. Ӓtiologie des morbus Crohn: Was spricht für Fette als mögliche Ursache? Deutsch Med Wochenschr 1983; 45: 1729–1733.
55. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992; 3: 47–52.
56. Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn’s disease. Br Med J (Clin Res Ed) 1987; 295: 517–520.
57. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 2254–2259.
58. Jowett SL, Seal CJ, Pearce MS et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004; 53: 1479–1484.
59. Sullivan SN. Hypothesis revisited: toothpaste and the cause of Crohn’s disease. Lancet 1990; 336: 1096–1097.
60. Evans SM, Ashwood P, Warley A et al. The role of dietary microparticles and calcium in apoptosis and interleukin-1beta release of intestinal macrophages. Gastroenterology 2002; 123: 1543–1553.
61. Lomer MC, Hutchinson C, Volkert S et al. Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn’s disease. Br J Nutr 2004; 92: 947–955.
62. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12(Suppl. 1): S3–S9.
63. Machella TE, Miller TG. Treatment of idiopathic ulcerative colitis by means of a “medical ileostomy” and an orally administered protein hydrolysate-dextrimaltose mixture. Gastroenterology 1948; 10: 28–45.
64. Lee EC, Papaioannou N. Minimal surgery for chronic obstruction in patients with extensive or universal Crohn’s disease. Ann R Coll Surg Engl 1982; 64: 229–233.
65. Kornbluth A. Infliximab approved for use in Crohn’s disease: A report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998; 4: 328–329.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Evaluation and treatment of portal hypertension
- Refeeding syndrome
- Desaturases of fatty acids (FADS) and their physiological and clinical implication
- Czech section of International College of Surgeons and Jubilee surgical world congress